Literature DB >> 15331063

Nonalcoholic fatty liver disease in the pediatric population.

Joel E Lavine1, Jeffrey B Schwimmer.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) covers the spectrum of features found in liver laden with macrovesicular fat and variable degrees of inflammation, cell injury, and fibrosis. By definition, NAFLD excludes those with significant ingestion of alcohol or alternative potential cause of steatohepatitis. NAFLD develops with rare exception in children who are obese. Given the rapid rise in prevalence of obesity in children globally, NAFLD is now recognized as the most common cause of liver disease in pediatrics. In obese individuals, Hispanic ethnicity and male gender appear to increase risk. Recent studies suggest that insulin resistance and oxidative stress are important in pathogenesis. Treatment trials are underway to determine if reduction of insulin resistance or oxidative stress will favorably affect outcome. This review summarizes what is known about pediatric nonalcoholic steatohepatitis in terms of prevalence, demographics, clinical presentation, histology,pathogenesis, and treatment. Important differences between pediatric and adult fatty liver disease are highlighted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331063     DOI: 10.1016/j.cld.2004.04.010

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  47 in total

1.  Traffic-related air pollution associations with cytokeratin-18, a marker of hepatocellular apoptosis, in an overweight and obese paediatric population.

Authors:  S Hsieh; B P Leaderer; A E Feldstein; N Santoro; L A McKay; S Caprio; R McConnell
Journal:  Pediatr Obes       Date:  2017-07-20       Impact factor: 4.000

2.  Availability of state-based obesity surveillance data on high school students with disabilities in the United States.

Authors:  Kiyoshi Yamaki; Brienne Davis Lowry; Emilie Buscaj; Leigh Zisko; James H Rimmer
Journal:  Matern Child Health J       Date:  2015-05

Review 3.  Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

Authors:  Anna Alisi; Ariel E Feldstein; Alberto Villani; Massimiliano Raponi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

4.  Risk factors and mechanisms of non-alcoholic steatohepatitis.

Authors:  Chantal A Rivera
Journal:  Pathophysiology       Date:  2008-07-29

5.  Direct and indirect effects of a family-based intervention in early adolescence on parent-youth relationship quality, late adolescent health, and early adult obesity.

Authors:  Mark J Van Ryzin; Paulina Nowicka
Journal:  J Fam Psychol       Date:  2013-02

6.  Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.

Authors:  Zhongbo Liu; Tianzhen Han; Haim Werner; Clifford J Rosen; Mitchell B Schaffler; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2017-11-06       Impact factor: 6.741

Review 7.  The metabolic syndrome and nonalcoholic fatty liver disease in children.

Authors:  Shikha S Sundaram; Phil Zeitler; Kristen Nadeau
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

8.  Anthropometric and metabolic characteristics in children with clinically diagnosed nonalcoholic fatty liver disease.

Authors:  Diana R Mager; Simon Ling; Eve A Roberts
Journal:  Paediatr Child Health       Date:  2008-02       Impact factor: 2.253

9.  Assessment of insulin resistance by a 13C glucose breath test: a new tool for early diagnosis and follow-up of high-risk patients.

Authors:  Meir Mizrahi; Gadi Lalazar; Tomer Adar; Itamar Raz; Yaron Ilan
Journal:  Nutr J       Date:  2010-05-27       Impact factor: 3.271

10.  Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels.

Authors:  Jean P Molleston; Jeffrey B Schwimmer; Katherine P Yates; Karen F Murray; Oscar W Cummings; Joel E Lavine; Elizabeth M Brunt; Ann O Scheimann; Aynur Unalp-Arida
Journal:  J Pediatr       Date:  2013-12-19       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.